Recessively Inherited Parkinsonism Effect of ATP13A2 Mutations on the Clinical and Neuroimaging Phenotype
Schilling Section of Clinical and Molecular Neurogenetics and Department of Neurology, University of Lübeck, Ratzeburger Allee 160, 23538 Lübeck, Germany. Archives of neurology
(Impact Factor: 7.42).
11/2010; 67(11):1357-63. DOI: 10.1001/archneurol.2010.281
To determine clinical features and to identify changes in brain structure and function in compound heterozygous and heterozygous ATP13A2 mutation carriers.
Prospective multimodal clinical and neuroimaging study.
University of Lübeck, Lübeck, Germany.
Eight family members of a large Chilean pedigree with Kufor-Rakeb syndrome (KRS).
Clinical characterization, dopamine transporter (DAT) imaging, voxel-based morphometry (VBM), and transcranial sonography (TCS).
Frequency of parkinsonian signs, brain structure, and functional alterations.
The only available patient with compound heterozygous KRS showed a markedly reduced striatal DAT density bilaterally. Magnetic resonance imaging revealed severe global brain atrophy as well as iron deposition in the basal ganglia. The heterozygous mother had definite parkinsonism with reduced DAT density in both putamina. While all asymptomatic heterozygous siblings displayed subtle extrapyramidal signs, DAT imaging revealed striatal tracer uptake within physiological levels. Voxel-based morphometry revealed an increase in gray matter volume in the right putamen and a decrease in the cerebellum of the heterozygous carriers. In all mutation carriers, the substantia nigra had a normal appearance on TCS.
Single ATP13A2 heterozygous mutations may be associated with clinical signs of parkinsonism and contribute to structural and functional brain changes. Lack of hyperechogenicity in the substantia nigra may be a distinctive feature of this form of genetic parkinsonism. This, along with the finding of iron in the basal ganglia in our patient with KRS, implies a different underlying pathophysiology compared with other monogenic forms of parkinsonism and idiopathic PD and may place KRS among the syndromes of neurodegeneration with brain iron accumulation (NBIA).
Available from: Peter Vangheluwe
- "ATP13A2 causes protection toward several heavy metals (Gitler et al., 2009; Schmidt et al., 2009; Kong et al., 2014) and in KRS patients iron deposits in the brain are observed (Bruggemann et al., 2010; Schneider et al., 2010). The prevailing hypothesis is therefore that ATP13A2 is a lysosomal cation pump (Gitler et al., 2009). "
[Show abstract] [Hide abstract]
ABSTRACT: Mutations in ATP13A2 lead to Kufor-Rakeb syndrome, a parkinsonism with dementia. ATP13A2 belongs to the P-type transport ATPases, a large family of primary active transporters that exert vital cellular functions. However, the cellular function and transported substrate of ATP13A2 remain unknown. To discuss the role of ATP13A2 in neurodegeneration, we first provide a short description of the architecture and transport mechanism of P-type transport ATPases. Then, we briefly highlight key P-type ATPases involved in neuronal disorders such as the copper transporters ATP7A (Menkes disease), ATP7B (Wilson disease), the Na(+)/K(+)-ATPases ATP1A2 (familial hemiplegic migraine) and ATP1A3 (rapid-onset dystonia parkinsonism). Finally, we review the recent literature of ATP13A2 and discuss ATP13A2's putative cellular function in the light of what is known concerning the functions of other, better-studied P-type ATPases. We critically review the available data concerning the role of ATP13A2 in heavy metal transport and propose a possible alternative hypothesis that ATP13A2 might be a flippase. As a flippase, ATP13A2 may transport an organic molecule, such as a lipid or a peptide, from one membrane leaflet to the other. A flippase might control local lipid dynamics during vesicle formation and membrane fusion events.
Frontiers in Molecular Neuroscience 05/2014; 7:48. DOI:10.3389/fnmol.2014.00048 · 4.08 Impact Factor
Available from: Marcel Benadiba
- "Another application for such neuroimaging methods is to grade the intensity of the loss of the striatal dopaminergic innervation and monitor the progression of the neurodegenerative process . Currently, increasing number of studies have also used functional neuroimaging as a tool to detect other non-dopaminergic abnormalities in patients with PD  , showing promising application in the investigation of a multitude of pathophysiological aspects related to the disease. "
[Show abstract] [Hide abstract]
ABSTRACT: The pathophysiology of Parkinson's disease (PD) has not yet been completely elucidated. However, during the past few years, significant progress has been made in understanding the intra- and extracellular mechanisms by which proteins such as alpha-synuclein and neuroinflammatory molecules may display impaired function and/or expression in PD. Recent developments in imaging techniques based on positron emission tomography (PET) and single photon emission computed tomography (SPECT) now allow the non-invasive tracking of such molecular targets of known relevance to PD in vivo. This article summarizes recent PET and SPECT studies of new radiopharmaceuticals and discusses their potential role and perspectives for use in the fields of new drug development and early diagnosis for PD, as well to aid in differential diagnosis and monitoring of the progression of PD.
08/2013; 3(3). DOI:10.3233/JPD-130207
Available from: Jin Chern Chiou
- "However, these two diseases involve different internal mechanisms and therefore require different clinical treatments (Draganski and Bhatia, 2010; Watts et al., 2011). Numerous studies have utilized brain imaging to probe alterations in the structural and functional organization of patients with PD (Kassubek et al., 2002; Brenneis et al., 2003; Burton et al., 2004; Price et al., 2004; Chebrolu et al., 2006; Beyer et al., 2007; Ramirez-Ruiz et al., 2007; Bouchard et al., 2008; Feldmann et al., 2008; Ibarretxe-Bilbao et al., 2008, 2009a, 2011a,b; Benninger et al., 2009; Camicioli et al., 2009; Cardoso et al., 2009; Jubault et al., 2009; Martin et al., 2009; Wattendorf et al., 2009; Agosta et al., 2010a,b; Bruggemann et al., 2010; Hamasaki et al., 2010; Focke et al., 2011). Over the past decade, the voxel-based morphometry (VBM) technique has been applied often for studying brain volume changes in PD and other degenerative brain diseases. "
[Show abstract] [Hide abstract]
ABSTRACT: Symptoms of essential tremor (ET) are similar to those of Parkinson's disease (PD) during their initial stages. Presently, there are few stable biomarkers available on a neuroanatomical level for distinguishing between these two diseases. However, few investigations have directly compared the changes in brain volume and assessed the compensatory effects of a change in the parts of the brain associated with PD and with ET. To determine the compensatory and/or degenerative anatomical changes in the brains of PD and ET patients, the present study tested, via two voxel-based morphometry (VBM) approaches (Basic vs. DARTEL VBM processing), the anatomical brain images of 10 PD and 10 ET patients, as well as of 13 age-matched normal controls, obtained through a 3T magnetic resonance scanner. These findings indicate that PD and ET caused specific patterns of brain volume alterations in the brains examined. In addition, our observations also revealed compensatory effects, or self-reorganization, occurring in the thalamus and the middle temporal gyrus in the PD and ET patients, due perhaps in part to the enhanced thalamocortical sensorimotor interaction and the head-eye position readjustment, respectively, in these PD and ET patients. Such a distinction may lend itself to use as a biomarker for differentiating between these two diseases.
Frontiers in Human Neuroscience 06/2013; 7:247. DOI:10.3389/fnhum.2013.00247 · 3.63 Impact Factor
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.